• Leukemias, lymphomas, and other hematologic cancers

Marqibo Generic Name & Formulations

General Description

Vincristine sulfate liposome injection; after preparation, each vial contains 0.16mg/mL; for IV infusion.

Pharmacological Class

Vinca alkaloid.

How Supplied

Kit—1 (vials + supplies)


Generic Availability


Marqibo Indications


Philadelphia chromosome-negative (Ph–) acute lymphoblastic leukemia (ALL) in second or greater relapse or has progressed following ≥2 anti-leukemia therapies.

Marqibo Dosage and Administration


Give 2.25mg/m2 IV over 1hr once every 7 days. Dose modifications for peripheral neuropathy: see full labeling.


Not established.

Marqibo Contraindications


Demyelinating conditions, including Charcot-Marie-Tooth syndrome. Intrathecal administration (death has occurred).

Marqibo Boxed Warnings

Boxed Warning

For IV use only; fatal if given by other routes. Marqibo has different dosage recommendations than vincristine sulfate injection; verify drug name and dose prior to administration.

Marqibo Warnings/Precautions


For IV use only; fatal if given by other routes. Discontinue and treat if extravasation is suspected. Preexisting neuromuscular disorders. Monitor for symptoms of neuropathy before and during therapy; if occurs or worsens, delay, reduce or discontinue dose. Monitor CBCs prior to each dose; if Grade 3 or 4 myelosuppression develops, consider dose delay or reduction. Monitor for tumor lysis syndrome; manage if occurs. Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction, and paralytic ileus; consider dietary fiber intake, hydration, stool softeners. Monitor liver function tests; if hepatotoxicity occurs, reduce or interrupt dosing. Elderly. Embryo-fetal toxicity. Advise to use effective contraception during and for 6 months (females of reproductive potential) or for 3 months (males w. female partners) after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for ≥1 week after the last dose).

Marqibo Pharmacokinetics

See Literature

Marqibo Interactions


Drugs known to interact with non-liposomal vincristine sulfate (eg, phenytoin: increased seizure risk). Avoid concomitant strong CYP3A inhibitors or strong CYP3A4 inducers. Avoid concomitant P-gp inhibitors or inducers.

Marqibo Adverse Reactions

Adverse Reactions

Constipation, nausea, pyrexia, fatigue (may be severe; adjust dose or discontinue), peripheral neuropathy, febrile neutropenia, diarrhea, anemia, decreased appetite, insomnia.

Marqibo Clinical Trials

See Literature

Marqibo Note

Not Applicable

Marqibo Patient Counseling

See Literature